Impact of the COVID-19 epidemic at a high-volume facility in gynecological oncology in Tokyo, Japan: a single-center experience

• Published in: Journal of ovarian research 2020-09, Vol.13 (1), p.105-105, Article 105
• Main Authors: Nogami, Yuya, Kobayashi, Yusuke, Tsuji, Kosuke, Yokota, Megumi, Nishio, Hiroshi, Nakamura, Masaru, Yamagami, Wataru, Morisada, Tohru, Tominaga, Eiichiro, Banno, Kouji, Aoki, Daisuke
• Format: Article
• Language: English
• Subjects: Betacoronavirus - isolation & purification; Cancer Care Facilities; Care and treatment; Case Report; Cervical cancer; Cervix; Chemotherapy; Clinical Decision-Making; Clinical Laboratory Techniques; Communicable diseases; Computed tomography; Coronaviridae; Coronavirus Infections - diagnosis; Coronavirus Infections - epidemiology; Coronavirus Infections - prevention & control; Coronaviruses; COVID-19; COVID-19 Testing; Decision making; DNA polymerases; Epidemics; Female; Genital Neoplasms, Female - therapy; Gynecological diseases; Health aspects; Humans; Infectious diseases; Middle Aged; Nosocomial infections; Oncology; Ovarian cancer; Ovarian tumor; Pandemics; Pandemics - prevention & control; Patients; Pneumonia; Pneumonia, Viral - diagnosis; Pneumonia, Viral - epidemiology; Pneumonia, Viral - prevention & control; Polymerase chain reaction; RNA-directed DNA polymerase; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Time-to-Treatment; Tokyo - epidemiology; Treatment Outcome; Tumors; Universal screening
• ISSN: 1757-2215; 1757-2215
• DOI: 10.1186/s13048-020-00711-x

The number of cases of novel coronavirus disease 2019 (COVID-19) in Japan have risen since the first case was reported on January 24, 2020, and 6225 infections have been reported as of June 30, 2020. On April 8, 2020, our hospital began screening patients via pre-admission reverse transcriptase-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and chest computed tomography (CT). Although no patients exhibited apparent pneumonia, treatment delay or changes in treatment plans were required for a few patients based on the results of screening tests. During an emerging infectious disease pandemic, the likelihood of being infected, as well as the disease itself, affects clinical decision making in several ways. We summarized and presented our experience. After the introduction of pre-admission screening, RT-PCR and CT were performed in 200 and 76 patients, respectively, as of June 30, 2020. The treatment of five patients, including two patients with cervical cancer, two patients with ovarian tumors, and one patient with ovarian cancer, was affected by the results. Two asymptomatic RT-PCR-positive patients did not develop COVID-19, but their treatment was delayed until the confirmation of negative results. The other three patients were RT-PCR-negative, but abnormal CT findings suggested the possibility of COVID-19, which delayed treatment. The patients receiving first-line preoperative chemotherapy for ovarian cancer had clinically evident exacerbations because of the treatment delay. During the epidemic phase of an emerging infectious disease, we found that COVID-19 has several other effects besides its incidence. The postponing treatment was the most common, therefore, treatment of ovarian tumors and ovarian cancer was considered to be the most likely to be affected among gynecological diseases. Protocols that allow for easy over-diagnosis can be disadvantageous, mainly because of treatment delays, and therefore, the protocols must be developed in light of the local infection situation.